Nimotuzumab and Docetaxel
Phase 3Small molecule
Nimotuzumab and Docetaxel is one of 61 small molecule programs targeting Lung Cancer. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
686 competitors in Lung Cancer
#DrugCompanyPhaseTrials
1Nimotuzumab and Docetaxel
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Libtayo
RegeneronPreclinical
Talzenna
PfizerPreclinical
Folvite
Eli LillyPreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Paclitaxel and Carboplatin
Bristol-Myers SquibbPreclinical
Acupan
YYonsei University
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
COVID-19 Vaccine
ModernaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nimotuzumab and Docetaxel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBiotech Pharmaceutical Co., Ltd.